OSTEOPORE LIMITED — Capital/Financing Update 2021

Jan 31, 2021

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

COOPERATION AGREEMENT WITH TERUMO BLOOD AND CELL TECHNOLOGIES TO PROMOTE AND SELL OSTEOPORE PRODUCTS

Highlights:

• Cooperation Agreement with Terumo Blood and Cell Technologies to promote and sell both companies complementary regenerative products in Asia-Pacific.

• Terumo Blood and Cell Technologies’ products will be used to concentrate a patient’s bone marrow and mixed into Osteopore scaffolds during implantation.

• The agreement will expose Osteopore products to Terumo Blood and Cell Technologies’ extensive network of blood centres, hospitals, therapeutic clinics, researchers, and private medical practices.

1 February 2021: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a revenuegenerating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, is pleased to announce a Cooperation Agreement with Terumo Blood and Cell Technologies whereby both companies will collaborate to promote and sell their respective regenerative products throughout the Asia-Pacific region.

Under the agreement, both groups will aim to establish commercial channels for the co-promotion of Terumo Blood and Cell Technologies’ Autologous Biologics (“TAB”) technology and Osteopore’s scaffolds. The TAB technology is used to concentrate the patient’s bone marrow and the concentrated autologous biologic can be mixed into Osteopore scaffolds during the implantation. The targeted applications include Neurosurgery, Orthopaedics and Reconstructive surgeries.

The companies’ technologies are complementary; Terumo Blood and Cell Technologies has unique equipment that can extract a patient’s bone marrow in a concentrated manner resulting in the potential to enhance bone regeneration. Osteopore’s scaffolds provide a biomimetic structure to guide bone tissue formation.

The agreement will expose Osteopore products to Terumo Blood and Cell Technologies’ extensive network of blood centres, hospitals, therapeutic clinics, researchers, and private medical practices in Asia-Pacific. Both companies will also evaluate opportunities for post-market and investigatorinitiated studies, using TAB and Osteopore products in selected countries to generate data to provide further support for future commercial activities.

Initially, the respective sales teams will undergo education for both products and develop a commercial strategy to offer regenerative cellular biologic concentration systems and scaffolds to meet surgeon and patient needs. The two companies also plan to co-sponsor several key events and workshops to promote the collaboration and their respective products.

Headquartered in Lakewood, Colorado, U.S.A., Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis, and cellular technologies. Its parent company, Terumo

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [130 x 44] intentionally omitted <==

Corporation, was founded in 1921 and is listed on the Tokyo Stock Exchange with annual revenues exceeding 600 billion Yen (A$8.0 billion).

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Carl Runde

Chief Financial Officer Osteopore Limited +61 4 0011 8017 carl_runde@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore’s patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing postsurgery complications commonly associated with permanent bone implants.

About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical device company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. TERUMOBCT.COM

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com